

Diabetes Screening for People with Schizophrenia, Schizoaffective Disorder or Bipolar Disorder Who Are Using Antipsychotic Medications

Diabetes and Antipsychotic Medications

Individuals with serious mental illness who use antipsychotics are at increased risk of diabetes.¹ Diabetes is the seventh leading cause of death in the United States.² Diabetes screening for members with schizophrenia, schizoaffective disorder or bipolar disorder who take antipsychotic medications is important for early detection and management.

Annual Diabetes Screening³

Annual diabetes screening for members 18 to 64 years old with schizophrenia, schizoaffective disorder or bipolar disorder is recommended if they receive an antipsychotic medication at any time during the year. Screen with either a glucose or HgbA1c test and document the result.

Medical Record Documentation and Best Practices

- Encourage shared decision-making by educating members and caregivers about:
 - Increased risk of diabetes with antipsychotic medications
 - Importance of screening for diabetes
 - Symptoms of new-onset diabetes
- Order a diabetes screening test every year and build care gap “alerts” in your electronic medical record
- Communicate and coordinate care between behavioral health and primary care physicians (PCPs) by requesting test results, communicating test results or scheduling an appointment for testing
- Reach out to members who cancel appointments and assist them with rescheduling as soon as possible
- Behavioral health practitioners:
 - Order diabetic screening tests for members who do not have regular contact with their PCP
 - Coordinate care and communicate test results to the member’s PCP

Behavioral Health Codes

Coding Instructions

Use ICD-10, CPT® and HCPCS to close gaps.

Glucose Test Codes

CPT: 80047-80048, 80050, 80053, 80069, 82947, 82950-82951

HgbA1c Codes

CPT: 83036-83037

CPT-CAT II: 3044F-3046F

Long-Acting Injections

HCPCS: C9035, C9037, J0401, J1631, J1942, J2358, J2426, J2794

Schizophrenia Codes

ICD-10: F20.0-F20.5, F20.81, F20.89, F20.9, F25.0-F25.1, F25.8-F25.9

Bipolar Disorder Codes

ICD-10: F30.10-F30.13, F30.2-F30.4, F30.8-F30.9, F31.10-F31.13, F31.2, F31.30-F31.32, F31.4-F31.5, F31.60-F31.64, F31.70-F31.78

BH Codes

CPT: 90791-90792, 90832-90834, 90836-90840, 90847, 90849, 90853, 90867-90870, 90875-90876, 99291

CPT copyright 2020 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

The above material is for informational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.

1 <https://www.ncqa.org/hedis/measures/diabetes-and-cardiovascular-disease-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/>; Accessed 1/21/20

2 <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm>; Accessed 1/21/20

3 NCQA HEDIS 2020 Technical specifications for health plans, volume 2, Washington DC, 2020. We collect certain data from our providers to measure and improve the quality of care our members receive.

Blue Cross®, Blue Shield® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans

Blue Cross and Blue Shield of Oklahoma, a Division of Health Care Service Corporation, a Mutual Legal